Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

被引：0
|
作者：
Pere Gascón
Matti Aapro
Heinz Ludwig
Carsten Bokemeyer
Mario Boccadoro
Matthew Turner
Kris Denhaerynck
Karen MacDonald
Ivo Abraham
机构：
[1] University of Barcelona,Division of Medical Oncology, Department of Hematology
[2] Clinique de Genolier,Oncology, Hospital Clínic de Barcelona
[3] Wilhelminenspital,Institut Multidisciplinaire d’Oncologie
[4] Universitaetsklinikum Hamburg Eppendorf,Medizinische Abteilung I–Onkologie und Haematologie
[5] Universitaria S. Giovanni Battista di Torino,Dipartimento di Oncologia e Ematologia, Azienda Ospedaliero
[6] Sandoz Biopharmaceuticals,Center for Health Outcomes and PharmacoEconomic Research
[7] University of Arizona,undefined
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：927 / 927
相关论文
共 50 条
  • [21] Cost savings of conversion from filgrastim or pegfilgrastim to biosimilar filgrastim-sndz for chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis and expanded access to biosimilar GCSF on a budget neutral basis.
    McBride, Ali
    Abraham, Ivo
    MacDonald, Karen
    Campbell, Kim
    Bikkina, Mohan
    Balu, Sanjeev
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (<24h), "per-guidelines" (24-72h), and "late" (>72h): findings from the MONITOR-GCSF study
    Ludwig, Heinz
    Gascon, Pere
    Bokemeyer, Carsten
    Aapro, Matti
    Boccadoro, Mario
    Denhaerynck, Kris
    Krendyukov, Andriy
    MacDonald, Karen
    Abraham, Ivo
    SUPPORTIVE CARE IN CANCER, 2019, 27 (06) : 2301 - 2312
  • [23] Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim
    Gascon, Pere
    Aapro, Matti
    Ludwig, Heinz
    Rosencher, Nadia
    Turner, Matthew
    Song, MinKyoung
    MacDonald, Karen
    Lee, Christopher
    Muenzberg, Michael
    Abraham, Ivo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 77 (03) : 184 - 197
  • [24] Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
    Otremba, Burkhard
    Hielscher, Carsten
    Petersen, Volker
    Petrik, Christian
    PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 2179 - 2186
  • [25] FITPATIENT: Biosimilar filgrastim for preventing chemotherapy-induced neutropenia
    Jost, E.
    Ottillinger, B.
    Bulenda, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 162 - 163
  • [26] Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
    Sophie Nahon
    Mansour Rastkhah
    Meher Ben Abdelghani
    Ravaka-Fatoma Soumoudronga
    Isabelle Gasnereau
    Jean-Luc Labourey
    Supportive Care in Cancer, 2016, 24 : 1991 - 1998
  • [27] ZarzioA®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
    Nahon, Sophie
    Rastkhah, Mansour
    Ben Abdelghani, Meher
    Soumoudronga, Ravaka-Fatoma
    Gasnereau, Isabelle
    Labourey, Jean-Luc
    SUPPORTIVE CARE IN CANCER, 2016, 24 (05) : 1991 - 1998
  • [28] Filgrastim - A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia
    Frampton, JE
    Faulds, D
    PHARMACOECONOMICS, 1996, 9 (01) : 76 - 96
  • [29] Supportive Treatment of Chemotherapy-Induced Neutropenia With Biosimilar Filgrastim: the HEXAFIL Non-Interventional Study
    Tesch, H.
    Indorf, M.
    Schaller-Kranz, T.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S280 - S281
  • [30] Prevention and Treatment of Chemotherapy-Induced Neutropenia with the Biosimilar Filgrastim: A Non-Interventional Observational Study of Clinical Practice Patterns
    Tesch, Hans
    Ulshoefer, Thomas
    Vehling-Kaiser, Ursula
    Ottillinger, Bertram
    Bulenda, Dietmar
    Turner, Matthew
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (04) : 146 - 152
12345